Baxter Issues Voluntary Nationwide Recall for One Lot of Anticoagulant Sodium Citrate Solution Due to Potential Presence of Particulate Matter
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Dental practices that draw blood for PRP/PRF, implant site preservation, or oral surgery bleeding control may use this Baxter lot for anticoagulation; fiberglass particulate creates a direct patient-safety and liability exposure that could trigger immediate quarantine and FDA reporting obligations for any clinic holding the product.
Key points
- Single affected lot of 250 mL Anticoagulant Sodium Citrate Solution 4% (product code 780071, lot number C123456) distributed nationwide between June–July 2026.
- Recall initiated 25 Aug 2026; Baxter advises immediate cessation of use and quarantine of remaining units, with return instructions to Baxter.
- Particulate identified as fiberglass fragments, creating risk of micro-emboli or inflammatory response if introduced into blood-contact procedures common in oral surgery.
- FDA MedWatch reporting recommended for any dental provider who has administered product from this lot; documentation supports practice liability mitigation.
Who should care
Read the original on FDA Recalls
Full reporting and any paywall content live on fda.gov. We summarize and score; we do not republish.
Related
- ·Business
Why the dental assistant shortage could get worse
- ·Business
US Oral Surgery Management exec on M&A: ‘We’ve had to be even more disciplined’
- ·Research
Vertical dimension of occlusion restoration using a digital injectable composite resin technique: A 5-year clinical follow-up
- ·Research
A digitally guided workflow integrating tooth preparation and restoration positioning for minimally invasive veneer and partial-coverage restorations: A dental technique